Bristol Myers Squibb Company $BMY Shares Sold by Manning & Napier Advisors LLC

Manning & Napier Advisors LLC lowered its stake in Bristol Myers Squibb Company (NYSE:BMY) by 46.4% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 211,054 shares of the biopharmaceutical company’s stock after selling 182,839 shares during the quarter. Manning & Napier Advisors LLC’s holdings in Bristol Myers Squibb were worth $9,519,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Arcadia Investment Management Corp MI lifted its stake in shares of Bristol Myers Squibb by 14.5% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 27,414 shares of the biopharmaceutical company’s stock worth $1,236,000 after acquiring an additional 3,475 shares during the period. WealthPLAN Partners LLC acquired a new position in shares of Bristol Myers Squibb during the third quarter valued at approximately $216,000. Plan Group Financial LLC bought a new stake in Bristol Myers Squibb during the third quarter worth approximately $205,000. GWN Securities Inc. lifted its position in Bristol Myers Squibb by 45.0% in the third quarter. GWN Securities Inc. now owns 14,165 shares of the biopharmaceutical company’s stock worth $641,000 after purchasing an additional 4,399 shares during the period. Finally, Retirement Planning Group LLC acquired a new position in shares of Bristol Myers Squibb during the 3rd quarter valued at $230,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $55.93 on Wednesday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The stock’s 50-day moving average is $51.33 and its two-hundred day moving average is $47.94. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. The firm has a market cap of $113.86 billion, a P/E ratio of 18.90, a PEG ratio of 9.23 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.52 by $0.11. The business had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. Bristol Myers Squibb’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be given a $0.63 dividend. The ex-dividend date is Friday, January 2nd. This represents a $2.52 annualized dividend and a yield of 4.5%. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio (DPR) is 85.14%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BMY. Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. The Goldman Sachs Group reissued a “neutral” rating and set a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Morgan Stanley reaffirmed an “underweight” rating and issued a $37.00 price target (up previously from $36.00) on shares of Bristol Myers Squibb in a report on Friday, December 12th. Finally, Leerink Partners raised their price objective on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday. Seven analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $56.86.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.